Viatris’ second quarter was met with a significant positive market reaction, as investors responded to operational execution and margin improvement despite year-over-year revenue declines. Management credited underlying momentum to strength in Europe and Greater China, along with progress on its pipeline and tighter cost controls. CEO Scott Smith noted that “five of our six anticipated Phase III readouts have shown positive results,” emphasizing advancements in the company’s late-stage development programs. The quarter also reflected benefits from portfolio diversification and ongoing remediation at manufacturing sites.
Is now the time to buy VTRS? Find out in our full research report (it’s free).
Viatris (VTRS) Q2 CY2025 Highlights:
- Revenue: $3.58 billion vs analyst estimates of $3.44 billion (5.6% year-on-year decline, 4.2% beat)
- Adjusted EPS: $0.62 vs analyst estimates of $0.56 (11.4% beat)
- Adjusted EBITDA: $1.08 billion vs analyst estimates of $1.04 billion (30.1% margin, 3.7% beat)
- The company reconfirmed its revenue guidance for the full year of $13.75 billion at the midpoint
- Management reiterated its full-year Adjusted EPS guidance of $2.23 at the midpoint
- EBITDA guidance for the full year is $4.04 billion at the midpoint, in line with analyst expectations
- Operating Margin: 6.5%, up from -6.3% in the same quarter last year
- Market Capitalization: $12.14 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Viatris’s Q2 Earnings Call
- Matthew Michael Dellatorre (Goldman Sachs) asked about capital allocation priorities and growth targets for 2026 and beyond. CEO Scott Smith emphasized a balanced approach between shareholder returns and strategic business development, aiming for sustainable long-term growth.
- Ashwani Verma (UBS) questioned the sustainability of China’s growth and the scope of the ongoing strategic review. Chief Commercial Officer Corinne Le Goff pointed to strong brand equity and diversified channels in China, while Smith highlighted expected cost savings from the review.
- David A. Amsellem (Piper Sandler) inquired about new product contributions in developed markets and updates on facility inspections. CFO Doretta Mistras said new product revenue remains back-half weighted, and management detailed progress at Indore and Nashik.
- Bhavin Patel (Bank of America) sought clarity on MR-141’s market positioning versus competitors and the drivers behind sequential gross margin improvement. Chief R&D Officer Philippe Martin differentiated MR-141’s mechanism and safety profile, while Mistras cited mix and cost initiatives for margin gains.
- No further analyst questions were noted on the call.
Catalysts in Upcoming Quarters
As we look to the upcoming quarters, our analysts will be monitoring (1) the pace of late-stage pipeline progress and associated regulatory approvals, (2) the outcome and disclosed impact of the enterprise-wide strategic review, and (3) sustained commercial execution in key regions such as Europe and Greater China. The timing and success of new product launches, especially in the Eye Care division and acute pain, will also be key indicators of future momentum.
Viatris currently trades at $10.65, up from $8.74 just before the earnings. Is there an opportunity in the stock?Find out in our full research report (it’s free).
Our Favorite Stocks Right Now
Trump’s April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.
Take advantage of the rebound by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
